Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
4(c) 3.65(c) 3.59(c) 3.41(c) 3.45 Last
68 683 144 806 196 544 118 049 103 559 Volume
-2.68% -8.75% -1.64% -5.01% +1.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1,61 M - -
Net income 2021 -94,6 M - -
Net cash position 2021 5,83 M - -
P/E ratio 2021 -1,53x
Yield 2021 -
Sales 2022 0,53 M - -
Net income 2022 -106 M - -
Net cash position 2022 63,4 M - -
P/E ratio 2022 -1,73x
Yield 2022 -
Capitalization 145 M 145 M -
EV / Sales 2021 86,8x
EV / Sales 2022 153x
Nbr of Employees 82
Free-Float 91,0%
More Financials
Company
Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its Microbiome Metabolic Therapies (MMTs) is designed to drive the function and distribution of the microbiomes existing microbes in order to decrease or increase the production of metabolites to certain bacteria in the microbiome community. The... 
More about the company
Ratings of Kaleido Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about KALEIDO BIOSCIENCES, INC.
11/15Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ..
GL
11/12Chardan Adjusts Price Target on Kaleido Biosciences to $11 From $15 on Pipeline Assets ..
MT
11/10Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer
GL
11/10Kaleido Biosciences, Inc. to Appoint Alison Long as Chief Medical Officer, Effective De..
CI
11/03JMP Securities Adjusts Price Target on Kaleido Biosciences to $22 From $25, Maintains M..
MT
11/01KALEIDO BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
11/01Press Release issued by Kaleido Biosciences, Inc., dated November 1, 2021, furnished he..
PU
11/01Kaleido Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
11/01Kaleido Biosciences Reports Third Quarter 2021 Financial Results
AQ
10/20NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
10/19KALEIDO BIOSCIENCES : Morgan Stanley Downgrades Kaleido Biosciences to Underweight from Eq..
MT
10/12KALEIDO BIOSCIENCES : to Participate in the Jefferies Virtual Next Generation IBD Therapeu..
AQ
10/05KALEIDO BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/05KALEIDO BIOSCIENCES : Says Bowel Disease Drug Trial Meets Primary Safety Endpoint
MT
10/05KALEIDO BIOSCIENCES : Announces New Clinical and Preclinical Data Supporting Advancement o..
AQ
More news
News in other languages on KALEIDO BIOSCIENCES, INC.
08/10Kaleido s'associe à la Fondation BPCO pour faire passer le KB109 à l'étude clinique de ..
07/02Kaleido Biosciences nomme Jerald Korn directeur de l'exploitation
More news
Analyst Recommendations on KALEIDO BIOSCIENCES, INC.
More recommendations
Chart KALEIDO BIOSCIENCES, INC.
Duration : Period :
Kaleido Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALEIDO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 3,45 $
Average target price 14,80 $
Spread / Average Target 329%
EPS Revisions
Managers and Directors
Daniel L. Menichella President, Chief Executive Officer & Director
William E. Duke Chief Financial Officer
Theo Melas-Kyriazi Chairman
Johan van Hylckama Vlieg Chief Scientific Officer
Kimberly Hocknell Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
KALEIDO BIOSCIENCES, INC.-62.53%145
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-40.67%24 625